Leon F. Schmidt-Jiménez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leon F. Schmidt-Jiménez has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Katja Bieber
Lübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany
3 shared publications - Ralf Joachim Ludwig
Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
3 shared publications - Stephanie Goletz
Lübeck Institute of Experimental Dermatology, University of Lübeck , Lübeck
3 shared publications - Enno Schmidt
Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
2 shared publications - Jennifer Elisabeth Hundt
Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
2 shared publications - Nina van Beek
Klinik für Dermatologie, Allergologie und Venerologie, Universitätsklinikum Schleswig-Holstein Campus Lübeck, Universität zu Lübeck, Lübeck, Deutschland
2 shared publications
Latest Publications
- Open Access
CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease
Pemphigoid diseases (PDs) are autoimmune disorders marked by autoantibodies (Aab) against skin and mucous membrane proteins, causing muco-cutaneous blistering in predominantly elderly patients. Since current therapeutics are often insufficient, PDs impose a significant morbidity and mortality burden. CD19×CD3 bispecific T cell engagers (TCEs) - originally developed for B cell malignancies - have shown promise in treatment-refractory autoimmune diseases like systemic sclerosis and rheumatoid arthritis. To explore their potential in PDs, we tested a murine CD19×CD3 TCE in a mouse model of epidermolysis bullosa acquisita (EBA), a prototypical PD. The TCE selectively depleted B cells in blood and bone marrow, but not spleen, of healthy mice. Mice with clinically manifest immunization-induced EBA were randomized to receive either the CD19×CD3 TCE or control treatment upon reaching a predefined disease severity. After 13 weeks, 45% of TCE-treated mice achieved remission, versus 23% of controls. This improvement correlated with reduced antigen-specific B cells, though total and antigen-specific IgG levels were unchanged. These findings suggest that CD19×CD3 TCE preferentially target autoreactive B cells and may be effective at lower doses than those used in oncology. Our data support the potential of CD19×CD3 bispecific T cell engagers as a therapeutic strategy for PDs. eTOC Synopsis: Gross, Jochimsen, Dräger and colleagues demonstrate that CD19×CD3 bispecific T cell engagers, can selectively target autoreactive B cells and induce remission in a mouse model of pemphigoid disease, highlighting their potential as a novel therapeutic strategy for autoimmune blistering disorders.
Open AccessCD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease
Pemphigoid diseases (PDs) are autoimmune disorders marked by autoantibodies (Aab) against skin and mucous membrane proteins, causing muco-cutaneous blistering in predominantly elderly patients. Since current therapeutics are often insufficient, PDs impose a significant morbidity and mortality burden. CD19×CD3 bispecific T cell engagers (TCEs) - originally developed for B cell malignancies - have shown promise in treatment-refractory autoimmune diseases like systemic sclerosis and rheumatoid arthritis. To explore their potential in PDs, we tested a murine CD19×CD3 TCE in a mouse model of epidermolysis bullosa acquisita (EBA), a prototypical PD. The TCE selectively depleted B cells in blood and bone marrow, but not spleen, of healthy mice. Mice with clinically manifest immunization-induced EBA were randomized to receive either the CD19×CD3 TCE or control treatment upon reaching a predefined disease severity. After 13 weeks, 45% of TCE-treated mice achieved remission, versus 23% of controls. This improvement correlated with reduced antigen-specific B cells, though total and antigen-specific IgG levels were unchanged. These findings suggest that CD19×CD3 TCE preferentially target autoreactive B cells and may be effective at lower doses than those used in oncology. Our data support the potential of CD19×CD3 bispecific T cell engagers as a therapeutic strategy for PDs. eTOC Synopsis: Gross, Jochimsen, Dräger and colleagues demonstrate that CD19×CD3 bispecific T cell engagers, can selectively target autoreactive B cells and induce remission in a mouse model of pemphigoid disease, highlighting their potential as a novel therapeutic strategy for autoimmune blistering disorders.
- Open Access
- 24 December 2024
- Published by Elsevier in JID Innovations
- Vol. 5 (3) , 100344
Meeting Report on “10th Anniversary Symposium on Inflammatory Skin Disease”
- 24 December 2024
- Published by Elsevier in JID Innovations
- Vol. 5 (3) , 100344
Open AccessMeeting Report on “10th Anniversary Symposium on Inflammatory Skin Disease”
- Open Access
- 18 December 2024
- Published by Elsevier in JID Innovations
- Vol. 5 (3) , 100342
Meeting Report on “The International Congress on Autoimmune Pre-disease (2024)”
- 18 December 2024
- Published by Elsevier in JID Innovations
- Vol. 5 (3) , 100342
Open AccessMeeting Report on “The International Congress on Autoimmune Pre-disease (2024)”
- 1 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (6) , 1552-1564.e8
Multiple Modes of Action Mediate the Therapeutic Effect of Intravenous IgG in Experimental Epidermolysis Bullosa Acquisita
- 1 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (6) , 1552-1564.e8
Multiple Modes of Action Mediate the Therapeutic Effect of Intravenous IgG in Experimental Epidermolysis Bullosa Acquisita